ZAI LAB(US:ZLAB) Seeking Alpha·2025-10-27 05:49Core Insights - Zai Lab is conducting a 2025 Triple Meeting Investor Call to discuss its global asset portfolio and clinical data updates [1][2] - The focus areas for Zai Lab's global development are oncology and immunology, with a particular emphasis on the Zoci program [3][4] Company Overview - Rafael Amado serves as the President and Head of Global Research and Development at Zai Lab [2] - The company is presenting updated clinical data for Zoci, a DLL3 targeted therapy, during the ENA Symposium in Boston [3][4] Clinical Development - Zai Lab is sharing results from the Phase I dose escalation and dose expansion clinical trials for Zoci, indicating progress in its oncology pipeline [3][4] - The presentation aims to clarify the implications of the clinical results for the Zoci program and outline next steps [3]